OMB No: 0910-0695 Expiration Date: 3/31/2024
Key
Information
Your
participation is voluntary.
You
are being asked to be part of an online (virtual) focus group
discussion about ways that you use and what you think about
prescription drug devices, like autoinjectors.
During
the discussion, we
will ask you to participate in some activities to help us
understand your opinions about your autoinjector. You will also be
asked to hold different versions of actual prescription drug
devices, and to talk about your experiences and opinions related to
them. (The devices will have no medicine or needles in them.)
The
virtual focus group discussion will take about 90 minutes.
To
the best of our knowledge, the things you will be doing have no
more risk of harm than you would experience in everyday life.
Focus Group Consent Form
What is the purpose of this study?
This study is designed to learn more about consumers’ perspectives on drug devices like autoinjectors.
If you take part in the study, you will be one of about 50 people to do so. You are being invited to participate in a research study, because you may have unique insights about how prescription drug devices are used.
Who is leading the study?
The person in charge of this study is Vanessa Boudewyns of RTI International, a nonprofit research institute. This research is being conducted on behalf of the U.S. Food and Drug Administration (FDA).
It is your choice to participate in this virtual focus group discussion. No one will be upset if you choose not to participate.
Even if you decide to be part of the study, you can stop participating at any time. You also do not have to answer any questions that you do not want to. You will receive payment as a token of our appreciation for your participation.
We are asking you to participate in a focus group discussion (with about 6 people) conducted online through an Internet platform called Zoom. Connecting to the platform is free.
You will be provided with instructions for joining the discussion and protecting your identity. Only first names will be used.
You will be in a Zoom meeting with an interviewer, a notetaker, and a few other people who are also participating in the discussion. In addition to the interviewer, who you will see onscreen, it is also possible that a few other research team members may observe the discussions so they can hear your opinions directly from you. However, they will not be visible, and they will not interact with you or the interviewer.
During the discussion, we will ask you about how you use different autoinjector drug devices and what you think about them. We will ask you to participate in group brainstorming activities. You will also be asked to hold different versions of actual autoinjector drug devices, and to talk about your experiences and opinions related to them. These autoinjectors contain no medicine or needles.
The focus group discussion will last about 90 minutes.
The organization that recruited you to participate will ask for your contact information to mail you a package of materials that you will need for the study. The package will include instructions, an activity sheet, and the devices that you will review during the discussion. You will be instructed to not open the package until after the focus group discussion begins.
We will video and audio record the discussions, and the recordings will be used to create transcripts. Only first names will be visible in the meeting, and only first names will be recorded. Staff members working on the project who were unable to watch the live streaming of the focus group will have access to the recording of the focus group ]
‘/ limited time after the discussion.
If you do not want to be video and audio recorded, or you do not consent to having the focus groups be live-streamed to remote staff, you will not be able to participate in the research.
The risks associated with participating in this focus group are the same as those you would experience talking in a group of people that you do not know.
You will be asked to hold an autoinjector and answer some questions about the device. The autoinjector is a trainer device; it does not contain medicine or a needle and it cannot be discharged. We will only ask you to hold and look at the device.
We do not expect that any of the topics discussed during the focus group will make you uncomfortable or upset you; however, if they do, you do not have to participate in that part of the discussion.
RTI will take steps to keep your participation secure to the extent provided by law. Even with these steps, there is still a small risk that your privacy could be broken.
The organization who recruited you to be part of the study will ask for your contact information to send you a package of materials you will need for the discussion. None of this information will be provided to RTI or FDA.
Throughout the study, RTI and FDA will not receive any record of your full name or contact information. This means that your personal information (name, address, phone number) will not be linked to any of your responses.
All data collected during the focus groups will be kept confidential to the extent provided by law. The study team will not disclose your name or any of your responses.
All data collected during the focus group will be stored in a secure server. In addition, all data transfers are protected by encryption.
In addition to these steps, we have obtained a Certificate of Confidentiality from FDA to help protect your privacy. This Certificate provides extra protection for you and your study information and documents. The Certificates are issued so that we cannot be required to disclose any identifiable, sensitive information collected about you as a part of this study in a lawsuit or legal proceeding. We are also prevented from releasing your study information without your consent. This is a layer of protection over and above the already existing protections in place.
There are no direct benefits to you for participating in this study. However, we will use the experiences and thoughts you share to improve the use of drug devices for people like you.
The transcripts from the focus group will be sent to FDA as part of a final report. When we analyze the results, your information will be separated from the information that identifies you, and it will be combined with information from other people taking part in the study.
We will write a report about all the focus groups and may use quotes from you in our report, but we will not use your name. You will not be identified in any published or presented materials. Nothing you say will be connected with your name.
Can my data be kept and used for other research studies?
Your data will not be used for any future research after this study is complete.
You will not be contacted in the future about this research after your participation in the focus group ends.
We will keep the video and audio recordings on a secure online server and destroy them at the end of the study. However, the transcripts will be sent to the FDA as part of a final report.
Before you decide whether or not to participate in the study, please ask any questions that come to mind. Later, if you have questions about the study, you can contact the investigator, Vanessa Boudewyns at 202-728-2092. She can be reached between 9:00 AM and 5:00 PM Central Time Monday to Friday.
The Institutional Review Board (IRB) at RTI International has reviewed this research. The IRB is an institutional review board, a group of people who are responsible for ensuring that the rights of participants in research are protected. The IRB is not involved in this study but may review the records of your participation in this research to ensure that proper procedures were followed. If you have questions about your rights as a study participant or concerns about how you are treated in the study, you may contact RTI’s Office of Research Protection at 1-866-214-2043.
You will be given a copy of this consent form to keep and we will keep a copy with the study records.
If you read the information above and agree to participate, please check the Yes button.
Yes, I agree to participate. No, I do not agree to participate.
DHHS research authorized by Section 1701(a)(4) of the Public Health Service Act (42 U.S.C. 300u(a)(4)). Confidentiality protected by 5 U.S.C. 552(a) and (b) and 21 CFR part 20.
OMB Control #0910-0695 Expires 02/28/2021
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
File Title | Consent Form |
Author | HAGERTY-HELLER_T |
File Modified | 0000-00-00 |
File Created | 2022-07-01 |